Please wait while the formulary information is being retrieved.
DACOGEN (DECITABINE)
- Myelodysplastic syndrome
50 mg intravenous solution
- Infuse 15 mg/m2 over 3 hour(s) by intravenous route every 8 hours
50 mg intravenous solution
- Infuse 15 mg/m2 over 3 hour(s) by intravenous route every 8 hours
Acute myeloid leukemia
- Infuse 20 mg/m2 over 1 hour(s) by intravenous route once daily
- Infuse 20 mg/m2 over 1 hour(s) by intravenous route once daily for 5 days
Myelodysplastic syndrome
- Infuse 15 mg/m2 over 3 hour(s) by intravenous route every 8 hours
- Infuse 15 mg/m2 over 3 hour(s) by intravenous route every 8 hours for3 days
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- None
DACOGEN (DECITABINE)
- Myelodysplastic syndrome
- Anemia
- Hyperglycemia
- Leukopenia
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Anorexia
- Chills
- Constipation
- Cough
- Diarrhea
- Dyspnea
- Ecchymosis
- Erythema
- Fatigue
- Fever
- Headache disorder
- Nausea
- Pallor
- Peripheral edema
- Petechiae
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Ascites
- Cellulitis
- Hyperkalemia
- Hypertension
- Hypoalbuminemia
- Hypokalemia
- Hypomagnesemia
- Hypotension
- Infection
- Lymphadenopathy
- Pulmonary edema
- Thrombocytosis
- Acute abdominal pain
- Acute confusion
- Alopecia
- Arthralgias
- Back pain
- Blurred vision
- Chest discomfort
- Chest pain
- Dizziness
- Dyspepsia
- Edema
- Epistaxis
- Facial edema
- General weakness
- Gingival bleeding
- Hematoma
- Hypesthesia
- Injection site sequelae
- Insomnia
- Lethargy
- Limb pain
- Malaise
- Myalgias
- Oral candidiasis
- Pain
- Pharyngitis
- Pruritus of skin
- Rales
- Sinusitis
- Skin lesion
- Stomatitis
- Toothache
- Upper respiratory infection
- Urinary tract infection
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Acute respiratory insufficiency
- Anaphylaxis
- Atrial fibrillation
- Bacteremia
- Cardiac arrest
- Cardiomyopathy
- Cholecystitis
- Fungal infection
- Hemoptysis
- Hyperbilirubinemia
- Intracranial bleeding
- Kidney disease with reduction in GFR
- Mycobacterium avium complex infection
- Pulmonary aspergillosis
- Pulmonary thromboembolism
- Renal failure
- Splenomegaly
- Sweet's syndrome
- Upper GI bleed
Less Severe
- Depression
- Dysphagia
- Gastroesophageal reflux disease
- Gingival pain
- Hemorrhoids
- Increased urinary frequency
- Sore tongue
- Tachycardia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Decitabine
Safety and efficacy not established in pediatrics < 18 years.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatrics < 18 years.
Decitabine
- Severity Level:
D
- Additional Notes: Available human data suggest increased risk of developmental toxicity.
Contraindicated
Decitabine
Not recommended; potential for serious adverse effects in infant.
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Not recommended; potential for serious adverse effects in infant. |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Myelodysplastic syndrome | |
| D46 | Myelodysplastic syndromes |
| D46.0 | Refractory anemia without ring sideroblasts, so stated |
| D46.1 | Refractory anemia with ring sideroblasts |
| D46.2 | Refractory anemia with excess of blasts [RAEb] |
| D46.20 | Refractory anemia with excess of blasts, unspecified |
| D46.21 | Refractory anemia with excess of blasts 1 |
| D46.22 | Refractory anemia with excess of blasts 2 |
| D46.4 | Refractory anemia, unspecified |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality |
| D46.Z | Other myelodysplastic syndromes |
| 0-9 | A-Z |
|---|---|
| D46 | Myelodysplastic syndromes |
| D46.0 | Refractory anemia without ring sideroblasts, so stated |
| D46.1 | Refractory anemia with ring sideroblasts |
| D46.2 | Refractory anemia with excess of blasts [RAEb] |
| D46.20 | Refractory anemia with excess of blasts, unspecified |
| D46.21 | Refractory anemia with excess of blasts 1 |
| D46.22 | Refractory anemia with excess of blasts 2 |
| D46.4 | Refractory anemia, unspecified |
| D46.9 | Myelodysplastic syndrome, unspecified |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts |
| D46.C | Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality |
| D46.Z | Other myelodysplastic syndromes |
Formulary Reference Tool